BigHat Biosciences, founded in 2019 in San Mateo, California, uses its Milliner platform, which combines AI with a high-speed lab, to design antibody drugs. It raised a $75 million Series C co-led by DFJ Growth and Premji Invest in September 2026, bringing total funding to $223 million.
At a glance
| Price from | Custom |
| Best for | Partners in oncology and antibody therapeutics |
From BigHat Biosciences's own website.
What stands out
- Lead program now in Phase 1
- Backed by Amgen, Eli Lilly and Merck's fund
Worth knowing
- Early clinical stage
- Smaller funding than the leaders
How it ranks
BigHat Biosciences is ranked 8th of 10 in Best AI Drug Discovery Startups (Lister Score 88.1).
#8 in Best AI Drug Discovery Startups · Lister Score 88.1
BigHat dosed the first patient in a Phase 1 study of BHB810, an antibody-drug conjugate for gastrointestinal cancers, in September 2026..
| Rank | Best AI Drug Discovery Startups | Score |
|---|---|---|
| 1 | Isomorphic Labs | 97.1 |
| 2 | Xaira Therapeutics | 95.8 |
| 3 | Chai Discovery | 94.6 |
| 4 | Enveda | 93.3 |
| 5 | insitro | 92.0 |
| 6 | Formation Bio | 90.7 |
| 7 | Genesis Molecular AI | 89.4 |
| 8 | BigHat Biosciences | 88.1 |
| 9 | Terray Therapeutics | 86.7 |
| 10 | Cradle | 85.3 |
Frequently asked questions
How does BigHat Biosciences rank on Lister?
BigHat Biosciences is ranked 8th of 10 in Best AI Drug Discovery Startups (Lister Score 88.1).
Appears in
Add this badge to your site
If you work at BigHat Biosciences, paste this code into your website to show where it ranks on Lister. The badge links to the ranking and updates within a day when the rank changes.